4OR Stock Overview
A biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
VivoSim Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.65 |
| 52 Week High | US$23.40 |
| 52 Week Low | US$2.53 |
| Beta | 1.2 |
| 1 Month Change | 0% |
| 3 Month Change | -23.70% |
| 1 Year Change | -75.69% |
| 3 Year Change | -91.26% |
| 5 Year Change | -98.46% |
| Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4OR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | 0.8% |
| 1Y | -75.7% | -13.5% | 15.0% |
Return vs Industry: 4OR underperformed the German Biotechs industry which returned -13.5% over the past year.
Return vs Market: 4OR underperformed the German Market which returned 15% over the past year.
Price Volatility
| 4OR volatility | |
|---|---|
| 4OR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 4OR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 4OR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 14 | n/a | www.organovo.com |
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company’s lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis.
VivoSim Labs, Inc. Fundamentals Summary
| 4OR fundamental statistics | |
|---|---|
| Market cap | €3.17m |
| Earnings (TTM) | -€11.02m |
| Revenue (TTM) | €108.51k |
Is 4OR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4OR income statement (TTM) | |
|---|---|
| Revenue | US$122.00k |
| Cost of Revenue | US$5.23m |
| Gross Profit | -US$5.11m |
| Other Expenses | US$7.27m |
| Earnings | -US$12.38m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jun 06, 2025
| Earnings per share (EPS) | -6.94 |
| Gross Margin | -4,190.16% |
| Net Profit Margin | -10,151.64% |
| Debt/Equity Ratio | 0% |
How did 4OR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 13:43 |
| End of Day Share Price | 2025/03/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
VivoSim Labs, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lavin | BTIG |
| Caroline Corner | Cantor Fitzgerald & Co. |
| Jose De Jesus Haresco | Citizens JMP Securities, LLC |